Warning Letter — Shang Hao Jia, Inc.
The FDA issued a Warning Letter to Shang Hao Jia, Inc. on March 18, 2026, following an inspection by the Office of Inspections and Investigations.
This affects Shang Hao Jia, Inc., specifically their regulatory compliance, quality assurance, and facility management departments.
An official Warning Letter indicates that the FDA has identified significant violations of regulatory requirements. Failing to adequately address these concerns could lead to further enforcement actions, such as seizures, injunctions, or administrative penalties. Regulatory professionals at the firm must prioritize a comprehensive response to mitigate legal and operational risks.
Facility management should conduct an immediate internal audit of the cited location to address specific violations noted by the Office of Inspections and Investigations. Ensure all corrective actions are documented and verifiable before submitting a formal response to the FDA.
FDA Warning Letter issued to: Shang Hao Jia, Inc.. 03/18/2026 — Office of Inspections and Investigations. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shang-hao-jia-inc-720238-03182026
Open in openFDA / FDA.gov